Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Abbott 3Q12 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Abbott 3Q12

Humira revenues dip as foreign currencies slide

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Abbott 3Q

3Q Revenues: $9.8 billion (-3%)

3Q Earnings: $1.9 billion (3Q11 earnings were $303 million)

YTD Revenues: $29.0 billion (+2%)

YTD Earnings: $4.9 billion (+58%)

Comments: Proprietary pharmaceutical sales dropped 4% in 3Q to $4.4 billion, due to currency fluctuation. U.S. proprietary pharma revenues were up 7% to $2.6 billion. Established pharma revenues dropped 7% to $1.3 billion. For YTD, proprietary pharma revenues were up
2% to $12.9 billion and established pharma revenues down 5% to $3.8 billion. Humira revenues were down 2% to $2.3 billion in the quarter, but up 27% in the U.S. to $1.1 billion. Humira sales YTD were up 6% to $6.6 billion. TriLipix sales rose 4% to $400 million in 3Q and are down 5% YTD at $1.1 billion. 3Q11 earnings were affected by a $1.4 billion legal charge.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters